Aprea Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Oren Gilad (CEO) and John P. Hamill (CFO) signed Sarbanes-Oxley Section 302 and 906 certifications on August 12, 2026 for the Q2 2026 10-Q (period ended June 30, 2026). Both certify the filing complies with SEC requirements, contains no untrue material statements, and fairly presents financial condition and results of operations. No new substantive business events, transactions, or financial data are disclosed in these certification exhibits.
Why this rating
Routine SOX certifications; boilerplate executive attestations required by law. No business event disclosed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.